EUCTR2004-000644-25-IT进行中（未招募）不适用
A Phase III, Open-Label, Multi-Center Clinical Trial to Evaluate the Safety and Efficacy of Insulin-Like Growth Factor I/ Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/ rhIGFBP-3), administered for 12 Months in Children and Adolescents with Growth Hormone Insensitive Syndrome (GHIS) such a Laron Syndrome.
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A PHASE III, OPEN-LABEL, MULTICENTRIC CLINICAL TRIAL OF A SINGLE ARM OF 16 LENGTHS OF TIME TO EVALUATE RETENTION WITH ELBASVIR / GRAZOPREVIR PLUS SOFOSBUVIR AND RIBAVIRIN IN PATIENTS WITH HEPATITIS C CHRONIC GENOTYPES 1.4 WHO HAVE FAILED TO TREAT WITH A REGIME BASED ON AN INHIBITOR OF THE NS5AEUCTR2017-000432-34-ESFundación SEIMC-GESIDA
进行中（未招募）
1 期
An open-label, phase I/II multicenter clinical trial of NECVAX-NEO1 as add-on to first-line neoadjuvant anti-PD-1 monoclonal antibody therapy in patients with triple-negative breast cancerCTIS2024-512520-11-00EC Bio Therapeutics GmbH8
已完成
2 期
An open-label, Phase I/II multicenter clinical trial of VXM01 in combination with avelumab in patients with progressive glioblastoma following standard treatment, with or without second surgery.GlioblastomaNL-OMON48738VAXIMM GmbH9
进行中（未招募）
1 期
An early phase clinical study of VXM01 in combination with avelumab in patients with brain cancer following standard treatment.Progressive glioblastoma (WHO grade IV)MedDRA version: 20.0 Level: PT Classification code 10018336 Term: Glioblastoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-003076-31-NLVAXIMM GmbH30
进行中（未招募）
1 期
An early phase clinical study of VXM01 in combination with avelumab in patients with brain cancer following standard treatment.EUCTR2017-003076-31-DEVAXIMM GmbH30